Gapping down
In reaction to disappointing earnings/guidance: FRAN -9.3%, URBN -2.7%, (disclosed thus far during Q2 comparable Retail segment net sales are mid single-digit positive), VIMC -2.5%, LMNR -1.7%, CLLS -1.5%
Other news: SALT -17.1% (announces public offering of $200 mln of common stock ), RXDX -4.5% ( announces public offering of $75 mln in common stock ), TRN -3.7% (announces a US District Court has entered judgment in the federal False Claims Act case filed against the company; intends to seek reversal of judgment), HRTX -3.4% (announces proposed underwritten offering of common stock), NRZ -3.3% ( announces the commencement of a public offering of 31,486,146 shares of its common stock; shares being sold by the company as well as selling shareholders), REGN -3.2% (FDA Advisory Committee votes 13-3 in favor of recommending FDA approval of PRALUENT (alirocumab) for the treatment of hypercholesterolemia ), NBG -3.2% (cont vol surrounding Greece negotiations), GPRO -3.2% (presenting at investor conf), GPOR -2.8% (announces agreements to acquire additional acreage, associated assets and incremental firm transportation commitments from American Energy Utica ), PACB -2.5% (still checking, may be in symp with REGN), TOF -2.2% (announced that President David Mintz, has successfully underwent surgery and expects to return to his duties this summer), CMRX -1.5% ( announces a $150 mln common stock offering), NEM -1.4% (prices its 29 mln share offering of common stock for total gross proceeds of ~$682 mln)
Analyst comments: DWA -1.9% (initiated with a Sell at Credit Agricole), HRB -0.9% (downgraded to Neutral from Outperform at Credit Suisse ), NVDA -0.8% (downgraded to Neutral from Buy at Nomura
)
In reaction to disappointing earnings/guidance: FRAN -9.3%, URBN -2.7%, (disclosed thus far during Q2 comparable Retail segment net sales are mid single-digit positive), VIMC -2.5%, LMNR -1.7%, CLLS -1.5%
Other news: SALT -17.1% (announces public offering of $200 mln of common stock ), RXDX -4.5% ( announces public offering of $75 mln in common stock ), TRN -3.7% (announces a US District Court has entered judgment in the federal False Claims Act case filed against the company; intends to seek reversal of judgment), HRTX -3.4% (announces proposed underwritten offering of common stock), NRZ -3.3% ( announces the commencement of a public offering of 31,486,146 shares of its common stock; shares being sold by the company as well as selling shareholders), REGN -3.2% (FDA Advisory Committee votes 13-3 in favor of recommending FDA approval of PRALUENT (alirocumab) for the treatment of hypercholesterolemia ), NBG -3.2% (cont vol surrounding Greece negotiations), GPRO -3.2% (presenting at investor conf), GPOR -2.8% (announces agreements to acquire additional acreage, associated assets and incremental firm transportation commitments from American Energy Utica ), PACB -2.5% (still checking, may be in symp with REGN), TOF -2.2% (announced that President David Mintz, has successfully underwent surgery and expects to return to his duties this summer), CMRX -1.5% ( announces a $150 mln common stock offering), NEM -1.4% (prices its 29 mln share offering of common stock for total gross proceeds of ~$682 mln)
Analyst comments: DWA -1.9% (initiated with a Sell at Credit Agricole), HRB -0.9% (downgraded to Neutral from Outperform at Credit Suisse ), NVDA -0.8% (downgraded to Neutral from Buy at Nomura
)